LoginGet started
Picture of Xbrane Biopharma AB logo

XBRANE — Xbrane Biopharma AB Income Statement

0.000.00%
se flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapSucker Stock
Balance sheetIncome statementCashflow
Subscribe to view all data

Annual income statement for Xbrane Biopharma AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.

R2019
December 31st
R2020
December 31st
2021
December 31st
2022
December 31st
2023
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:ARSInterim ReportARSARSARS
Standards:
IFRS		—
IFRS
IFRS
IFRS
Status:FinalFinalFinalFinalFinal
Revenue
Total Revenue00057.6239
Cost of Revenue
Gross Profit-18.300—35.4
Selling / General / Administrative Expenses
Research And Development
Other Operating Expenses
Total Operating Expenses187217181224561
Operating Profit-187-217-181-166-322
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes-188-218-183-169-322
Provision for Income Taxes
Net Income After Taxes-188-218-183-169-322
Minority Interest
Net Income Before Extraordinary Items
Extraordinary Items
Net Income-188-226-188-173-388
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income-188-226-188-173-388
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS-1.85-1.37-0.88-0.747-1.27
Dividends per Share